68 results about "Viral Inactivation" patented technology

The invention provides a decellularized dermal matrix particle and a preparation method thereof, the preparation method comprises the steps of pretreatment, degreasing, virus inactivation, decellularization, grinding, crosslinking, freeze-drying and sterilization subpackaging, and solves the problems that the existing decellularized particle product is non-uniform in particle size, incomplete in decellularization, poor in injection effect and incapable of meeting the requirements of tissue repair and regeneration. The invention develops a product which is short in production cycle, relatively concentrated in particle size distribution, thorough in cell removal and complete in matrix function preservation, can effectively remove fat and viruses in animal skin, and has the advantages of being thorough in decellularization, short in time, high in efficiency, light in damage to dermal matrix, capable of removing antigens, capable of retaining a natural structure and capable of effectively guiding tissue regeneration. When the temperature of the freeze-dried particle dispersion liquid is reduced, the water binding capacity of the particles is reduced, free water in the prepared solution is increased, the particles naturally float and gather (dense at the upper part and sparse at the lower part), and the free water is in the lower layer and still has good dispersity after being sterilized.

The invention provides a method for detecting a virus inactivation effect by an ELISA (Enzyme-Linked Immunosorbent Assay) method, which comprises the following steps: acquiring a to-be-detected inactivated virus sample, extracting an antigen component from the sample, and detecting an antigen structure change characteristic value through a high-throughput mass spectrometry analysis technology to obtain antigen degradation degree data; obtaining a sample subjected to preliminary inactivation, and detecting the antigen content change trend through an enzyme-linked immunosorbent assay to obtain content change curve data; detecting the residual quantity of viral nucleic acid by a real-time fluorescent quantitative PCR (Polymerase Chain Reaction) technology aiming at the immunogenicity retained sample to obtain nucleic acid degradation degree data; acquiring nucleic acid degradation degree data, classifying the relationship between nucleic acid residues and infectivity by adopting a support vector machine algorithm, and judging that the inactivation effect is completely completed if the classification result shows that the infectivity is lost; according to the antigen content change trend, the immunogenicity index and the nucleic acid degradation degree data, a weighted fusion algorithm is adopted to integrate multi-dimensional detection results, and a comprehensive inactivation effect score is obtained.

The invention provides a larimichthys crocea iridovirus inactivated vaccine as well as a preparation method and application thereof, and belongs to the technical field of preparation of viral vaccines. The larimichthys crocea iridovirus inactivated vaccine comprises an inactivated larimichthys crocea iridovirus and an adjuvant, and the strain of the larimichthys crocea iridovirus is an FD201807 strain. After the larimichthys crocea iridovirus inactivated vaccine is injected, the phenomena of ingestion and abnormal behaviors of fishes are avoided, the death phenomenon is avoided, the safety is high, the relative immune protection rate of the inactivated vaccine to immunized fishes is 51.20% or above, the immune effect is good, and the larimichthys crocea iridovirus inactivated vaccine can be applied to prevention and treatment of larimichthys crocea iridovirus diseases. The preparation method of the larimichthys crocea iridovirus inactivated vaccine is simple and convenient, easy to operate, low in cost and suitable for industrial production.

The invention relates to a heat-resistant H1N1 subtype influenza virus mutant vaccine strain and application thereof. The invention belongs to the technical field of virus gene engineering, and particularly discloses a heat-resistant H1N1 subtype influenza virus mutant vaccine strain and application thereof. According to the H1N1 subtype influenza virus mutant vaccine strain and the preparation method thereof, the HA protein head region, which is a key region influencing the virus thermal stability, is mutated, the virus thermal stability can be remarkably improved only by mutating three amino acid sites, meanwhile, the virus still has good thermal stability after being inactivated, the H1N1 subtype influenza virus mutant vaccine strain prepared by HA protein point mutation has the preservation number of CCTCC NO: V202471, and the H1N1 subtype influenza virus mutant vaccine strain can be used for preparing the H1N1 subtype influenza virus mutant vaccine strain. And immune animals can be induced to generate high-level HI antibodies.

The invention relates to the technical field of biological medicines, in particular to a soluble skin-adhering microneedle for delivering an inactivated enterovirus vaccine as well as a preparation method and application of the soluble skin-adhering microneedle. Sodium hyaluronate is adopted as a film forming material to wrap an enterovirus 71 type (EV71)-coxsackie virus A16 (CA16) type bivalent inactivated vaccine antigen, and a needle body layer of the soluble microneedle is formed; the substrate layer is prepared from a pullulan material, so that the microneedle patch with a stable overall structure is formed. The technology provided by the invention is completed in a clean environment, and the vaccine patch which is qualified through sterility detection is obtained. The soluble microneedle disclosed by the invention has good antigen stability under the condition of 2-8 DEG C. In animal experiments, the microneedle is attached to the skin surface of a mouse for skin-adhering immunization, a strong immune response reaction can be induced, good immunogenicity is shown, and a novel, safe and effective vaccine delivery way is provided for prevention and control of the infantile hand-foot-and-mouth disease.

The invention provides a rabies virus inactivated vaccine and a preparation method thereof, and belongs to the technical field of biological medicines. The invention provides a rabies virus inactivated vaccine. The rabies virus inactivated vaccine comprises an adjuvant and an inactivated VSV-rabies recombinant virus, the inactivated VSV-rabies recombinant virus is obtained by carrying out inactivation on a VSV-rabies recombinant live virus; the VSV-rabies recombinant live virus is prepared by replacing envelope protein G of vesicular stomatitis virus with G protein of rabies virus. The inactivated rabies virus vaccine is good in safety and high in induced antibody level, the immune effect of the inactivated rabies virus vaccine is equivalent to that of a live virus vector vaccine, and the inactivated rabies virus vaccine has a certain application value in the aspect of preventing and controlling rabies.

The invention discloses a recombinant Getai virus for expressing H1N1 subtype swine influenza virus HA protein, the virus has an H1N1 subtype swine influenza virus HA1 protein gene, and the HA1 protein gene is located between E1 and 3 'UTR genes of a Getai virus genome. Accordingly, a corresponding construction method is also established. Furthermore, a corresponding recombinant Geitai virus inactivated vaccine is also developed. Researches show that the inactivated vaccine is used for immunizing mice, can well induce test animals to generate specific antibodies aiming at the H1N1 subtype swine influenza virus, also can generate specific antibodies for expressing the Geitai virus, and provides immune protection for attack of the H1N1 subtype swine influenza virus; and the H1N1 subtype swine influenza virus and Getah virus bivalent inactivated vaccine is successfully prepared. Therefore, the invention has a better effect on prevention and control of the H1N1 subtype swine influenza virus, lays a foundation for the Geitai virus as a carrier to express other exogenous genes, is expected to be used clinically, and can protect a pig farm from being attacked by the two viruses at the same time.

The invention discloses an akabane virus inactivated vaccine preparation method, which comprises: carrying out Vero cell passage in a cell bottle, taking well growing cells until the cells grow to 80-90%, adding into a DMEM culture medium containing 10% of fetal calf serum, taking out the cells growing to 80-90% and having a good state, adding akabane virus CH-JL-01-2022 according to a volume ratio of 0.1%, and carrying out culture at a temperature of 80-90 DEG C so as to obtain the akabane virus inactivated vaccine. Culturing for 2-3 days in an incubator with the temperature of 37 DEG C and 5% CO2; the method comprises the following steps: preparing 0.25 M BEI, 0.1 M BPL and a 40% formaldehyde solution as inactivators, setting five concentration gradients according to the volume ratios of 0.01%, 0.05%, 0.1% and 0.5%, and collecting after 6 hours, 12 hours, 24 hours, 36 hours and 48 hours after adding; the screening of the akabane virus inactivation conditions according to the types, concentrations and inactivation time of inactivators finds that 0.5% formaldehyde shows a complete inactivation effect after inactivation for 36 hours. The inactivated virus liquid is mixed with MONTANIDETM ISA 201, an ImjectI aluminum adjuvant and a manganese adjuvant according to the volume ratio of 1: 1, and then immunization is carried out, and the protection effect of the ImjectI aluminum adjuvant is found to be optimal.

A viral inactivation device including at least one experimental continuous viral inactivation reactor having at least an inlet, an outlet, and a tubular flow path and a computer system that, based on the experimental continuous viral inactivation reactor can design, select, make, and / or manufacture a scaled actual reactor. The tubular flow path includes a set of alternating turns that form a serpentine or an interwoven pattern between the inlet and the outlet.

The invention provides an application of trichostatin A in promotion of RNA virus proliferation, and belongs to the field of chemical medicines. The invention discloses a novel application of trichostatin A. The trichostatin A can effectively promote the-1 Ribosomal Frameshift process of RNA viruses, can effectively promote replication and proliferation of the RNA viruses, can be used for preparing products for promoting proliferation of the RNA viruses and can be used for producing and preparing RNA virus inactivated vaccines or attenuated vaccines, and the application of the trichostatin A in promoting proliferation of the RNA viruses and the application of the trichostatin A in promoting proliferation of the RNA viruses and the application of the trichostatin A in promoting proliferation of the RNA viruses and the application of the trichostatin A in promoting proliferation of the RNA viruses and the application of the trichostatin A in promoting proliferation of the RNA viruses and the application of the trichostatin A in promoting proliferation of the RNA viruses. And the production cost can be effectively reduced, the production period is shortened, and wide application prospects and economic values are achieved.

The invention belongs to the field of biology, and particularly relates to a method for improving sample turbidity of three antibodies in virus inactivation and neutralization processes. Carrying out virus inactivation on the chromatographic eluent containing the three antibodies, neutralizing the solution after virus inactivation, and filtering after neutralization to obtain a clear filtrate; the neutralization method comprises the following steps: diluting the final concentration of a chromatographic eluent to 1.7 g / L by using 0.1 M Gly-HCl with the pH value of 3.2, and neutralizing and adjusting by using 0.2 M PB with the pH value of 7.0 until the pH value is 7.0-8.0; or 0.2 M NaCl is used for diluting the final concentration of the chromatographic eluent to 1.7 g / L, then 1M Tris-HCl and pH 9.0 are used for neutralization adjustment, and the pH is neutralized to 7.0-8.0. By adopting the neutralization method in the anti-virus inactivation process, the sample is not turbid or precipitated, and the recovery rate is high.

Viral inactivation apparatus and method for the inactivation of live virus species. A fluid flow bioreactor is provided having an elongate flow channel adapted to control fluid flow characteristics of a solution containing suspended viral particles for irradiation by a suitable radiation source to produce inactive viral species suitable for vaccine synthesis. The present bioreactor configuration is advantageous to control administration of irradiation dosage to reliably and efficiently create inactivated viral species at 100% effectiveness whilst preserving structural integrity of the viral species so as to provide an effective inactivated vaccine.

The present invention belongs to the field of surface skin repair and wound treatment, and specifically relates to a new type of wound dressing, a preparation method and application thereof. The preparation method comprises: preparation and preliminary purification of hemoglobin, fine purification of hemoglobin, degassing treatment, virus inactivation, preparation of wound dressing stock solution and preparation of wound dressing. The wound dressing can be used for wound treatment on the skin surface, especially for the treatment of chronic wounds, especially for the treatment of chronic wounds with delayed healing for more than 8 weeks, especially for ulcers caused by basic metabolic diseases such as diabetes, neuropathic or ischemic ulcers, leg venous insufficiency, ulcers caused by external pressure after skin and tissue aging (such as pressure sores, bedsores), second-degree and below burns, frostbite, etc., especially foot ulcers caused by diabetes; it can also be used for scar repair on the skin surface, and can also be used for repairing difficult-to-heal wounds after surgery.

The application belongs to the technical field of protein purification, and particularly relates to a recombinant human metapneumovirus pre-fusion F protein purification method, which comprises the following steps: filtering fermentation broth by using a deep filter to obtain fermentation clarified liquid; capturing the recombinant hMPV F protein from the fermentation clarified liquid by using hydroxyapatite to obtain purified liquid 1; inactivating viruses in the purified liquid 1 by using a low-pH method to obtain inactivated liquid; performing anion exchange chromatography on the inactivated liquid to obtain purified liquid 2; performing composite weak anion chromatography on the purified liquid 2 to obtain purified liquid 3; performing UF / DF on the purified liquid 3 to obtain ultrafiltrate; and performing virus-removing nanofiltration and sterile filtration on the ultrafiltrate to obtain a recombinant hMPV F stock solution. The method is simple, reproducible, suitable for large-scale production, and can be effectively used for producing a recombinant human metapneumovirus pre-fusion F protein vaccine.

A viral inactivation composition includes an aqueous solution of citric acid and L-arginine hydrochloride with a pH below 3.5. The citric acid and L-arginine hydrochloride are present in amounts that directly inactivate COVID-19, influenza, and common cold virus in a human upper respiratory system. A method of directly inactivating COVID-19, influenza, and common cold virus in the human upper respiratory system includes administering the viral inactivation composition to a subject. These ingredients are safe, non-toxic, and very effective.

The application discloses a natural recombination novel duck reovirus variant (NDRV-GXNN-2025) strain, which has a preservation number of CCTCC No:V202613 and a preservation date of January 28, 2026. Researches show that the NDRV-GXNN-2025 strain has high pathogenicity to ducklings and goslings, and the mortality rates of 2-day-old ducklings and goslings are 30% and 50% respectively when the attack dose is 104.0 / 0.1ml; meanwhile, the strain has good immunogenicity and is an ideal vaccine candidate strain. Accordingly, the inventors also establish a preparation method of a corresponding inactivated vaccine. The novel duck reovirus inactivated vaccine prepared by the method has good stability and safety, can induce the body to produce high-level neutralizing antibodies after immunizing ducklings and goslings, and can effectively resist the attack of the novel duck reovirus variant, and has a good application prospect.

The present invention relates to a multi-stage decellularized mammal-derived tissue supplement, prepared by a method comprising: a preparation step for preparing tissue of a non-human mammal; a pretreatment step for pretreating the tissue; a first inactivation step for inactivating a virus included in the pretreated tissue using alcohol; a primary decellularization step for removing cells from the virus-inactivated tissue using an aqueous basic solution; a secondary decellularization step for removing cells by enzymatically treating the primary decellularized tissue; and a second inactivation step for inactivating a virus included in the decellularized tissue using an acid, and wherein the DNA content in the tissue subjected to the pretreatment step to the second inactivation step is 50 ng / mg or less, and the degradation time using 100 U / ml of collagenase is at least 90 hours; and a method for preparing the same.

A viral inactivation device including at least one experimental continuous viral inactivation reactor having at least an inlet, an outlet, and a tubular flow path and a computer system that, based on the experimental continuous viral inactivation reactor can design, select, make, and / or manufacture a scaled actual reactor. The tubular flow path includes a set of alternating turns that form a serpentine or an interwoven pattern between the inlet and the outlet.

A virus inactivator composition, characterized in that it contains: (a) 0.01% to 5.0% by mass of a cationic virus inactivating component as a virus inactivating component; (b) 0.02% to 10.0% by mass of one or more selected from fumaric acid, phosphoric acid, lactic acid and citric acid as a virus inactivation efficacy enhancing component; and water.

The present invention provides intravenous pharmaceutical compositions comprising engineered plant virus-based nanoparticles for the treatment or prevention of autoimmune conditions. The nanoparticles display immunodominant peptides that induce immune tolerance in a subject when administered intravenously. The invention further provides methods of manufacturing virus-based nanoparticles, including production in plant expression systems and optional viral inactivation, to render them suitable for therapeutic use in mammals. Also provided are methods of intravenous administration of the pharmaceutical compositions to a subject in need thereof for treating or preventing autoimmune conditions.

The present invention discloses a sputum specimen collection robot, wherein a track is preset along the walking route of the device, a matching track wheel is arranged on the track, the wheel axle of the track wheel is fixed in the bearing of a base, a power motor for driving the wheel axle to rotate is arranged on the bottom surface of the base, a constant temperature box is fixed on the base, and at least one group of sampling mechanisms is arranged in the constant temperature box; the present invention has the advantages of high automation, medical personnel can complete the acquisition of sputum samples without contacting patients, and can pre-treat and crush the sputum samples, and can inactivate viruses at the same time, so that subsequent laboratory testing work will not cause external pollution and infection.

To satisfy a need for methods and reagents utilized during sample handling for viral inactivation, thereby rendering samples non-infectious and providing safer sample handling conditions.SOLUTION: Methods of utilizing sample lysis reagent compositions in handling of samples containing viruses, such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), are disclosed. The reagent composition comprises a nonionic octylphenol ethoxylate surfactant and water. Kits containing the sample lysis reagent compositions are also disclosed.SELECTED DRAWING: Figure 1

To provide a compact virus infection preventing apparatus capable of effectively preventing virus infection, having high treatment capacity for inactivating viruses and good in operability.SOLUTION: In the virus infection prevention device, the air washing section includes a tubular barrel section having a connection port with the air supply hose at one end and an opening at the other end, a first air supply fan and a first ultraviolet light emitting diode provided in this order inward of the connection port, a second air supply fan and a second ultraviolet light emitting diode provided in this order inward of the opening, and a reflecting mirror between the first ultraviolet light emitting diode and the second ultraviolet light emitting diode. The reflecting mirror has a cylindrical body portion, a first inclined portion provided at one end portion of the cylindrical body portion and substantially matching a light distribution angle of ultraviolet rays emitted from the first ultraviolet ray emitting diode, and a second inclined portion provided at the other end portion of the cylindrical body portion and substantially matching a light distribution angle of ultraviolet rays emitted from the second ultraviolet ray emitting diode.SELECTED DRAWING: Figure 2

The application relates to a tube reactor module for controlling a reaction time of a process fluid in dynamic operation, in particular during viral inactivation in the process fluid, comprising: an inlet for receiving the process fluid; an outlet for discharging the process fluid; a tubular flow path comprising a serpentine pattern for guiding the process fluid from the inlet to the outlet, the tubular flow path comprising a sequence of fluidly connected alternatingly bent curve sections, wherein each curve section is shaped such that a flow direction of the process fluid changes by at least approximately 90°, in particular by between approximately 135° and 225°, and wherein the tubular flow path comprises a first cross-section perpendicular to the flow direction of the process fluid at respective apexes of the curve sections and a second cross-section perpendicular to the flow direction of the process fluid at respective end portions of the curve sections, wherein the first cross-section is different from the second cross-section.

The present invention provides a mediated CA16 inactivated vaccine, comprising an immunizing amount of CoxA16 virus inactivated purified antigen, and also comprising glycerol, sucrose, squalene, Tween-20 and heparan sulfate. The present invention provides a mediated CA16 inactivated vaccine that can be used to prepare immunization through a specific immune mode. After the vaccine product enters the respiratory mucosal cells through cell internalization, it can stimulate the natural immune system in the epithelial cells, promote the recognition of viral antigens by the DC system and T / B cells, and the activation and differentiation of the specific immune system.

The invention relates to a method for purifying a target substance starting from a fluid to be treated which comprises at least one impurity. The method comprises treatment of a stream of the fluid to be treated using a chromatography step in a first separation unit, collection of a fraction enriched with the target substance in a first tank, and viral inactivation of the fraction enriched with the target substance. The viral inactivation comprises passing the fraction enriched with the target substance through a second separation unit, passing a viral inactivation solution through the second separation unit, mixing, and collecting the mixture in the second tank to obtain a fraction depleted of active virus. The method further comprises treatment of the fraction depleted of active virus using a chromatography step in the second separation unit and collection of a fraction more enriched with the target substance.

To provide a virus inactivator that exhibits a viral inactivation effect for envelope viruses and also exhibits a superior viral inactivation effect for non-envelope viruses.SOLUTION: A virus inactivator comprising a phytic acid and at least one of the following component (A) and component (B). Component (A): at least one alkanediol selected from the group consisting of 1,2-pentanediol, 1,2-hexanediol, 1,2-heptanediol, 1,2-octanediol, and 1,2-decanediol. Component (B): at least one oily component selected from the group consisting of lavender oil, camphor leaf oil, rosemary oil, peppermint oil, copaiba oil, squalane, and liquid paraffin.SELECTED DRAWING: None

The invention relates to a method for inactivating an enveloped virus in a biopharmaceutical-containing fluid, said method comprising exposing said fluid to a substituted cyclodextrin. The invention also relates to a method for purifying and / or producing a biopharmaceutical comprising exposing a biopharmaceutical-containing fluid to a substituted cyclodextrin.

The present invention relates to a multi-stage decellularized mammal-derived tissue matrix, prepared by a method comprising: a preparation step for preparing tissue of a non-human mammal; a pretreatment step for pretreating the tissue; a first inactivation step for inactivating a virus included in the pretreated tissue using alcohol; a primary decellularization step for removing cells from the virus-inactivated tissue using an aqueous basic solution; a secondary decellularization step for removing cells by enzymatically treating the primary decellularized tissue; and a second inactivation step for inactivating a virus included in the decellularized tissue using an acid, and wherein the DNA content in the tissue subjected to the second inactivation step is 50 ng / mg or less, and the reduction rate (L) of the elastin content in the tissue subjected to the pretreatment step to the second inactivation step is 20% or less; and a method for preparing the same.

The content of the invention consists in the concept of an intelligent object / room supply and disinfection system which is harmless to health and the mode of action of which is based on the use of electromagnetic waves of the UV spectral range both for the generation of the bacterial and viral disinfection potential and for the transmission of audio, video and data information. The invention is directed to the operability of the following classes or areas of application and ensures bacterial and viral inactivation of animate stationary and mobile enclosed or semi-enclosed:1. large objects such as cultural, sports and event venues;2. institutional and public objects such as buildings of public life, health care, education and higher education;3. cabins such as the passenger cabins of land, air and sea passenger transportation means;4. objects of animal breeding, animal husbandry and veterinary medicine.The inactivation is based on the continuous-wave interaction of electromagnetic radiation fields within the wavelength range between 190 nm and 230 nm and the programmable and / or auto-adaptive generation capability of continuous and / or discrete radiation spectra with controllable temporal and spatial signal signatures.